

Supporting Information

Redox condensation of *o*-Halonitrobenzene with 1,2,3,4-Tetrahydroisoquinoline: Involvement of an Unexpected Auto-catalyzed Redox Cascade

Thanh Binh Nguyen,* Ludmila Ermolenko, and Ali Al-Mourabit*

General information


Reagents were obtained from commercial supplier and used without further purification. Analytical thin layer chromatography (TLC) was purchased from Merck KGaA (silica gel 60 F254). Visualization of the chromatogram was performed by UV light (254 nm) or phosphomolybdic acid or vanilline stains. Flash column chromatography was carried out using kieselgel 35-70 µm particle sized silica gel (230-400 mesh). NMR Chemical shifts are reported in (δ) ppm relative to tetramethylsilane (TMS) with the residual solvent as internal reference (CDCl_3 , δ 7.26 ppm for ^1H and δ 77.0 ppm for ^{13}C ; CD_3OD , δ 3.31 ppm for ^1H and δ 49.0 ppm for ^{13}C ; DMSO-d_6 , δ 2.50 ppm for ^1H and δ 39.5 ppm for ^{13}C). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz) and integration.

General procedure

A mixture of **1** (1 mmol) and **2** (2.5 mmol) was stirred at 130 °C or 150 °C (see Table 1, Schemes 4 and 5 of the manuscripts for details) for 24 h under an argon atmosphere. The cooled reaction mixture was diluted with methanol and treated with a saturated ammonia solution in methanol (0.5 mL). The resulting solution was concentrated in vacuo. The residue was purified by silica gel column chromatography (heptane: EtOAc 4:1 to EtOAc) to afford the fused benzimidazole **5**.

Characterizations of Products

2-(2-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline (3aa)¹




¹ Hedley, K. A.; Stanforth, S. P. *Tetrahedron* **1992**, *48*, 743.

Purification with silica gel column chromatography (EtOAc:heptane : 50:1) as an orange solid. mp. 100 °C (lit. 100-102 °C).¹

¹H NMR (300 MHz, CDCl₃) δ 7.83-7.80 (m, 1H), 7.50-7.44 (m, 1H), 7.23-7.08 (m, 5H), 7.00-6.95 (m, 1H), 4.33 (s, 2H), 3.40 (t, *J* = 5.5 Hz, 2H), 3.02 (t, *J* = 5.5 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 145.7, 141.8, 134.7, 133.9, 133.6, 128.9, 126.8, 126.6, 126.5, 126.3, 120.4, 120.0, 52.7, 50.3, 29.0.

5,6-Dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline 12-oxide (4aa)




The product was obtained as a white solid by filtration of the reaction mixture in DMF diluted in CH₂Cl₂.

¹H NMR (300 MHz, DMSO-d₆) δ 9.38-9.33 (m, 1H), 7.79-7.74 (m, 2H), 7.49-7.43 (m, 4H), 7.37-7.31 (m, 1H), 4.43 (t, *J* = 6.8 Hz, 2H), 3.30 (t, *J* = 6.8 Hz, 2H).

¹³C NMR (75 MHz, DMSO-d₆) δ 134.1, 133.9, 133.6, 130.3, 128.3, 128.2, 127.1, 125.5, 124.8, 122.4, 122.0, 113.2, 111.3, 40.4, 27.6.

5,6-Dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5aa)²




Purification of the crude mixture (Table 1, entry 2) by silica gel column chromatography (EtOAc) afforded the product as a yellow powder (30 mg, 55%), (196 mg, 89%).

¹H NMR (300 MHz, CDCl₃) δ 8.12 (d, *J* = 6.5 Hz, 1H), 7.67 (m, 1H), 7.46 (m, 1H), 7.40 (m, 3H), 7.27 (m, 2H), 4.31 (t, *J* = 6.8 Hz, 2H), 3.25 (t, *J* = 6.8 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 148.9, 142.7, 135.3, 134.3, 130.4, 128.1, 127.3, 125.7, 124.8, 122.8, 122.5, 118.2, 109.5, 40.2, 27.7.

10-Methyl-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ba)³



Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (201 mg, 86%).


² Oconnell, J. M.; Moriarty, E.; Aldabbagh, F. *Synthesis* **2012**, *44*, 3371.

³ Sun, X.; Lv, X. H.; Ye, L. M.; Hu, Y.; Chen, Y. Y.; Zhang, X. J.; Yan, M. *Org. Biomol. Chem.* **2015**, *13*, 7381.

¹H NMR (300 MHz, CDCl₃) δ 8.20 (dd, *J* = 6.3, 2.6 Hz, 1H), 7.52 (m, 1H), 7.31 (m, 2H), 7.21 (m, 1H), 7.13 (d, *J* = 8.1 Hz, 1H), 7.01 (dd, *J* = 8.1, 1.5 Hz, 1H), 4.20 (t, *J* = 7.0 Hz, 2H), 3.18 (t, *J* = 7.0 Hz, 2H), 2.42 (s, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 149.0, 144.1, 134.2, 132.2, 130.0, 128.0, 127.7, 127.0, 125.6, 124.2, 123.5, 119.5, 108.2, 40.5, 28.3, 21.8.

10-Methoxy-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ca)




Purification of the crude mixture by silica gel column chromatography (EtOAc: heptane 1:4) afforded the product as a yellow powder (175 mg, 70%).

¹H NMR (300 MHz, CDCl₃) δ 8.21 (dd, *J* = 6.8, 2.2 Hz, 1H), 7.34 (m, 2H), 7.26 (m, 1H), 7.18 (m, 2H), 6.87 (dd, *J* = 8.8, 2.2 Hz, 1H), 4.25 (t, *J* = 7.8 Hz, 2H), 3.83 (s, 3H), 3.23 (t, *J* = 7.8 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 156.5, 141.7, 140.1, 133.9, 130.2, 128.1, 127.8, 125.5, 113.1, 109.5, 101.8, 55.8, 40.5, 28.3.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₆H₁₅N₂O : 251.1184; found : 251.1173.

10-(Trifluoromethyl)-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5da)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (250 mg, 87%).

¹H NMR (300 MHz, CDCl₃) δ 8.29 (m, 1H), 8.09 (s, 1H), 7.52 (dd, *J* = 8.5, 1.4 Hz, 1H), 7.43 (m, 3H), 7.34 (m, 1H), 4.36 (t, *J* = 6.9 Hz, 2H), 3.32 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.9, 143.3, 136.6, 134.4, 130.8, 128.2, 127.9, 126.0, 125.9, 124.9 (q, *J* = 270.0 Hz), 124.8 (q, *J* = 32.0 Hz), 119.6 (q, *J* = 3.5 Hz), 117.3 (q, *J* = 4.5 Hz), 109.4, 40.6, 28.0.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₆H₁₂F₃N₂ : 289.0953; found : 289.0941.

10-Chloro-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ea)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (194 mg, 76%).

¹H NMR (300 MHz, CDCl₃) δ 8.27 (m, 1H), 7.78 (t, *J* = 1.3 Hz, 1H), 7.40 (m, 2H), 7.33 (m, 1H), 6.23 (m, 2H), 4.28 (t, *J* = 6.8 Hz, 2H), 3.27 (t, *J* = 6.8 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.3, 144.8, 134.2, 133.4, 130.6, 128.2, 128.0, 127.8, 126.2, 125.8, 123.0, 119.5, 109.7, 40.6, 28.2.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₂ClN₂: 255.0689; found : 207.0681.

9-Chloro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5fa)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (220 mg, 86%).

¹H NMR (300 MHz, CDCl₃) δ 8.18 (m, 1H), 7.62 (d, *J* = 8.5 Hz, 1H), 7.34 (m, 2H), 7.26 (d, *J* = 8.5 Hz, 2H), 7.15 (d, *J* = 8.5, 1.8 Hz, 1H), 4.23 (t, *J* = 6.9 Hz, 2H), 3.21 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.0, 142.5, 135.4, 134.3, 130.6, 128.2, 127.9, 127.3, 125.8, 125.7, 125.2, 120.5, 109.3, 40.6, 28.2.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₂ClN₂: 255.0689; found : 207.0694.

8-Chloro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5ga)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (190 mg, 75%).

¹H NMR (300 MHz, CDCl₃) δ 8.30 (m, 1H), 7.70 (dd, *J* = 8.5 Hz, 1H), 7.44 (m, 2H), 7.35 (m, 1H), 7.23 (m, 2H), 4.85 (t, *J* = 6.9 Hz, 2H), 3.28 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.3, 145.8, 134.4, 130.5, 127.9, 127.8, 126.3, 126.0, 124.1, 122.9, 118.6, 116.1, 111.2, 42.6, 28.6.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₂ClN₂: 255.0689; found : 207.0678.

8,9-Dichloro-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ha)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (211 mg).

¹H NMR (300 MHz, CDCl₃) δ 8.25 (m, 1H), 7.62 (d, *J* = 8.6 Hz, 1H), 7.43 (m, 2H), 7.34 (m, 2H), 4.88 (t, *J* = 6.8 Hz, 2H), 3.29 (t, *J* = 6.8 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.8, 144.0, 134.3, 131.9, 130.7, 127.9, 127.8, 127.4, 126.0, 124.2, 118.8, 114.7, 111.7, 42.7, 28.3.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₁Cl₂N₂: 289.0299; found : 289.0288.

10-Fluoro-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ia)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (185 mg, 78%).

¹H NMR (300 MHz, CDCl₃) δ 8.25 (m, 1H), 7.47 (dd, *J* = 9.5, 2.4 Hz, 1H), 7.39 (m, 2H), 7.29 (m, 1H), 7.22 (2d, *J* = 9.0, 4.4 Hz, 1H), 7.00 (td, *J* = 5.0, 2.5 Hz, 1H), 4.28 (t, *J* = 6.9 Hz, 2H), 3.25 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 159.4 (d, *J* = 238 Hz), 150.4, 144.1, 134.0, 131.2, 130.4, 128.1, 127.8, 126.2, 125.6, 110.9 (d, *J* = 27 Hz), 109.3 (d, *J* = 10 Hz), 105.4 (d, *J* = 24 Hz), 40.4, 27.9.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₂FN₂: 239.0985; found : 239.0991.

10-Bromo-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ja)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (209 mg, 70%).

¹H NMR (300 MHz, CDCl₃) δ 8.18 (m, 1H), 7.86 (d, *J* = 1.6 Hz, 1H), 7.33 (m, 2H), 7.29 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.23 (m, 1H), 7.13 (d, *J* = 8.5 Hz, 1H), 4.28 (t, *J* = 6.9 Hz, 2H), 3.27 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.0, 144.7, 134.2, 133.5, 130.7, 128.1, 127.8, 125.9, 125.8, 125.0, 122.3, 115.5, 110.4, 40.6, 28.0.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₂BrN₂: 299.0184; found : 299.0179.

Ethyl 5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline-10-carboxylate (5ka)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:4) afforded the product as a yellow powder (230 mg, 79%).

¹H NMR (300 MHz, CDCl₃) δ 8.54 (s, 1H), 8.31(m, 1H), 8.02 (d, *J* = 8.2 Hz, 1H), 7.39 (m, 4H), 4.42 (m, 4H), 3.32 (t, *J* = 6.8 Hz, 2H), 1.43 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 167.1, 150.6, 143.1, 137.7, 134.4, 130.7, 128.1, 127.9, 126.0, 125.1, 124.4, 123.3, 121.8, 108.8, 60.9, 40.6, 28.0, 14.7.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₈H₁₇N₂O₂: 293.1290; found : 293.1296.

5,6-Dihdropyrido[2',3':4,5]imidazo[2,1-*a*]isoquinoline (5la)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:1) afforded the product as a yellow powder (159 mg, 72%).

¹H NMR (300 MHz, CDCl₃) δ 8.37 (d, *J* = 4.7 Hz, 1H), 8.30 (m, 1H), 8.07 (d, *J* = 8.2 Hz, 1H), 7.45 (m, 2H), 7.37 (m, 1H), 7.25 (m, 1H), 4.53 (t, *J* = 6.8 Hz, 2H), 3.32 (t, *J* = 6.8 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 150.2, 147.5, 143.6, 136.4, 135.3, 131.1, 128.3, 127.8, 127.0, 126.2, 125.8, 118.6, 39.4, 28.0.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₄H₁₂N₃: 222.1031; found : 222.1042.

10-Bromo-5,6-dihdropyrido[2',3':4,5]imidazo[2,1-*a*]isoquinoline (5ma)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:1) afforded the product as a yellow powder (204 mg, 68%).

¹H NMR (300 MHz, CDCl₃) δ 8.25 (d, *J* = 2.0 Hz, 1H), 8.09 (m, 1H), 8.00 (d, *J* = 2.0 Hz, 1H), 7.31 (m, 2H), 7.21 (m, 1H), 4.33 (t, *J* = 6.9 Hz, 2H), 3.19 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 151.0, 146.1, 144.1, 137.3, 135.1, 131.2, 129.2, 128.9, 128.2, 127.7, 125.6, 113.8, 39.1, 28.0.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₄H₁₁BrN₃: 300.0136; found : 300.0142.

2-Bromo-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ab)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:1) afforded the product as a yellow powder (197 mg, 66%).

¹H NMR (300 MHz, CDCl₃) δ 8.46 (d, *J* = 1.7 Hz, 1H), 7.83(m, 1H), 7.50 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.34 (m, 3H), 7.20 (d, *J* = 8.2 Hz, 1H), 4.34 (t, *J* = 6.9 Hz, 2H), 3.25 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 147.6, 143.7, 134.6, 133.2, 132.9, 129.7, 128.7, 128.4, 123.1, 122.8, 121.6, 119.9, 109.3, 40.3, 27.7.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₅H₁₂BrN₂: 299.0184; found : 299.0199.

3-Methoxy-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ac)




Purification of the crude mixture by silica gel column chromatography (EtOAc:CH₂Cl₂ 1:1) afforded the product as a yellow powder (197 mg, 66%).

¹H NMR (300 MHz, CDCl₃) δ 8.15 (d, *J* = 8.7 Hz, 1H), 7.74-7.67 (m, 1H), 7.26-7.14 (m, 3H), 6.86 (dd, *J* = 8.7, 2.4 Hz, 1H), 6.75 (d, *J* = 2.4 Hz, 1H), 4.21(t, *J* = 6.9 Hz, 2H), 3.78 (s, 3H), 3.16 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 161.4, 149.6, 144.1, 136.4, 134.8, 129.7, 127.6, 122.4, 119.6, 119.5, 113.8, 113.3, 109.0, 55.6, 40.5, 28.7.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₆H₁₅N₂O: 251.1184; found : 251.1193.

2,3-Dimethoxy-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ad)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:1) afforded the product as a yellow powder (168 mg, 60%).

¹H NMR (300 MHz, CDCl₃) δ 7.74 (m, 1H), 7.71 (s, 1H), 7.27 (m, 1H), 7.19 (m, 2H), 6.72 (s, 1H), 4.23 (t, *J* = 6.9 Hz, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 3.16 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (75 MHz, CDCl₃) δ 150.8, 149.3, 148.7, 143.8, 134.7, 127.5, 122.4, 122.3, 119.5, 119.2, 110.9, 109.0, 108.2, 56.4, 56.1, 40.6, 27.9.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₇H₁₇N₂O₂: 281.1290; found : 281.1279.

7,12-Dihydro-6*H*-benzo[4',5']imidazo[1',2':1,2]pyrido[3,4-*b*]indole (5ae)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:1) afforded the product as a pale yellow powder (150 mg, 58%).

¹H NMR (300 MHz, CDCl₃) δ 12.72 (broad s, 1H), 7.89-7.86 (m, 1H), 7.76-7.73 (m, 1H), 7.56-7.23 (m, 6H), 4.60 (t, *J* = 6.9 Hz, 2H), 3.57 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 145.9, 143.4, 138.4, 135.0, 126.2, 125.1, 124.1, 123.1, 122.7, 120.3, 119.4, 119.3, 113.9, 112.9, 109.4, 42.1, 20.9.

HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₇H₁₄N₃: 260.1188; found : 260.1193

2-(Trifluoromethyl)-7,12-dihydro-6*H*-benzo[4',5']imidazo[1',2':1,2]pyrido[3,4-*b*]indole (5af)




Purification of the crude mixture by silica gel column chromatography (EtOAc:heptane 1:1) afforded the product as a pale yellow powder (150 mg, 58%).


¹H NMR (300 MHz, CDCl₃) δ 12.23 (broad s, 1H), 8.03 (broad s, 1H), 7.68-7.49 (m, 3H), 7.31-7.17 (m, 3H), 4.53 (t, *J* = 6.9 Hz, 2H), 3.50 (t, *J* = 6.9 Hz, 2H).

¹³C NMR (75 MHz, CDCl₃) δ 147.7, 143.1, 138.5, 137.1, 126.1, 124.8, 124.7 (q, *J* = 273 Hz) 124.4 (q, *J* = 32 Hz), 120.7, 120.1 (q, *J* = 3.7 Hz), 119.6, 116.7 q, *J* = 4.0 Hz, 114.9, 112.7, 109.6, 42.4, 20.8.


HRMS-ESI+: *m/z* [M + H]⁺ calcd for C₁₈H₁₃F₃N₃: 328.1062; found : 328.1073.


5,6-Dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline 12-oxide (4aa)







2-(2-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline (3aa)







5,6-Dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5aa)







10-Methyl-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5ba)







10-Methoxy-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ca)







10-(Trifluoromethyl)-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5da)







10-Chloro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5ea)







9-Chloro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5fa)







8-Chloro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5ga)







8,9-Dichloro-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ha)







10-Fluoro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5ia)







10-Bromo-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ja)







Ethyl 5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline-10-carboxylate (**5ka**)







5,6-Dihydropyrido[2',3':4,5]imidazo[2,1-*a*]isoquinoline (5la)







10-Bromo-5,6-dihydropyrido[2',3':4,5]imidazo[2,1-a]isoquinoline (5ma)







2-Bromo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (5ab)







3-Methoxy-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ac)







2,3-Dimethoxy-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (5ad)





7,12-Dihydro-6H-benzo[4',5']imidazo[1',2':1,2]pyrido[3,4-*b*]indole (5ae)





2-(Trifluoromethyl)-7,12-dihydro-6H-benzo[4',5']imidazo[1',2':1,2]pyrido[3,4-b]indole (5af)

